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 ABSTRACT
Introduction. Multiple sclerosis (MS) is the most common non-traumatic neurological cause of disability in young adults, 
affecting women 1-3 times more often than men. Several specific challenges arise from the fact that young women diagnosed 
with MS often have to make decisions related to treatment and family planning at the same time. These issues are connected 
with fertility, the impact of pregnancy on disease course, the choice of pregnancy timing, and the optimal mode of disease-
-modifying therapy in the context of a planned pregnancy, contraception, urological complaints, and sexual dysfunction. 
State of the art. While MS does not in itself adversely affect fertility, pregnancy or childbirth, pregnancy needs to be carefully 
planned. This requires the interdisciplinary co-operation of a neurologist, gynaecologist and psychologist. Data on the impact 
of disease-modifying drugs on foetal development are very limited, and none of these drugs is 100% safe during pregnancy. In 
the second and third trimesters, MS relapse rate decreases. Unfortunately, it increases within the first 3-6 months after delivery. 
Adequate disease control should be achieved before pregnancy, as relapse rate in the period of two years preceding pregnancy 
is one of the strongest predictive factors for post-partum relapses.
Clinical implications. The following is a statement by a working group of experts in neurology, gynaecology, obstetrics and 
urology, convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society, addressing 
the issues that are specific to the female MS population. The aim of this statement is to provide guidance in pregnancy planning 
and disease management, both during pregnancy and post-partum. 
Future directions. This statement reflects expert opinion and is not intended to be read as guidelines. It rather provides up-to-
-date information on how to optimise care of female MS patients of childbearing age. 
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Introduction
Multiple sclerosis (MS) is the most common neurolo-
gical disease that causes disability in young adults [1]. The 
mean age of onset is about 30 years. Most studies report 
a higher prevalence of MS among women. The female-to-
-male ratio varies from 1.1 to 3 in relapsing-remitting MS
(RRMS). Women and men are equally affected by primary
progressive MS, which accounts for up to 10% of all MS
cases [2]. In practice, MS is most prevalent among women
of childbearing age. Studies show that only 21% of wo-
men decide to have offspring after the establishment of MS
diagnosis, meaning that 79% of women with MS exclude
motherhood — 34.5% justify their decision with disease-
-related factors (e.g. the fear that their condition will not allow 
them to raise children, the fear of passing the disease onto the 
child) [3]. In fact, the probability of a child whose parent is
affected by MS developing the disease is low (approx. 2–3%).
Nonetheless, it is 15 times higher than in the general popu-
lation [4]. Moreover, the disease does not adversely affect
pregnancy or childbirth [5, 6]. When one parent is affected by 
MS, the risk of the disease for each child is 2.5% [7]. When MS 
is diagnosed in both parents, the risk of MS in a child reaches 
12.2% [8]. However, the disease is not hereditary.
Epidemiology of multiple sclerosis 
The worldwide incidence and prevalence of MS are highly 
variable, both in terms of genetic and geographical factors. 
The number of patients with MS is estimated at 2.5 million 
worldwide, while in Europe it is around 630,000 patients [9]. 
After considering epidemiological data from neighbouring 
countries and research from selected regions of Poland, the 
estimated number of MS patients in Poland is approximately 
45,000 [10]. 
Nearly 5% of the world’s population develops autoimmune 
diseases, 78% of whom are female [11]. The main theory expla-
ining MS pathogenesis is based on the autoimmune concept 
[12]. Hence, it is not surprising that women are more affected by 
MS. The potential risk factors include genetic factors (targeted 
inactivation of the second X chromosome, foetal microchi-
merism) and hormonal factors (e.g. by oestrogen receptors). 
Several environmental factors have a significant influence 
on disease distribution and prevalence [13], including Epstein-
-Barr virus (EBV) infection, exposure to sunlight and the level 
of Vitamin D, the effect of which may be particularly important 
in the prenatal period. A recent large prospective analysis
of 77,330 women from the Danish National Birth Registry
(1996–2002) [14] indicated new risk factors in the female
population. An inverse relationship was observed between
age at first menarche and the risk of MS. For each one-year
increase in age at menarche, the risk of the disease was reduced 
by 13%. However, the mechanism that could account for this
relationship remains unknown.
Although genetic factors seem to be strongly associated 
with predisposition to the disease, specific genes related di-
rectly to MS risk have not been identified yet [15].   
 Fertility of patients with multiple sclerosis 
There is no evidence for an association between men-
strual cycle disorders and the development of MS. As in 
the general population, about 15% of couples with MS have 
problems with conception. The prevalence of sexual dys-
function in MS is estimated at 40% among women and 65% 
among men [16]. Studies show that the mean time from first 
attempts to conceive to the confirmation of pregnancy was 
seven months. However, this period was sometimes extended 
to nine months. This time was not statistically significantly 
different between the group of women with MS and the 
general population. According to Finnish data, the need for 
artificial insemination was greater in the group of women 
with MS [17]. Previous disease-modifying drugs (DMDs) 
had no impact on this period. Of note, unsuccessful attempts 
at in vitro fertilisation and administration of gonadotropin-
-releasing hormone agonists were associated with a higher
risk of relapse. If the partner is affected by MS, ejaculation
disorders and more frequent urinary tract infections (UTIs) 
are possible. Consequently, deterioration of semen parame-
ters can be observed.
Influence of pregnancy on the course of 
multiple sclerosis 
Pregnancy in Multiple Sclerosis (PRIMS), which included 
254 women, was the first prospective study assessing the 
impact of pregnancy on MS [18]. It showed a decrease in 
relapses during pregnancy (by about 70%) and an increase in 
the postpartum period (particularly the first three months). It 
was also found that the occurrence of relapses after pregnancy 
depended mainly on relapse activity before pregnancy. 
Further studies [19, 20, 21] did not show long-term ef-
fects of pregnancy on the natural course of the disease, and 
even suggested its protective effect by showing that women 
with a history of multiple births had lower disability and/or 
reached a particular level of disability during a longer period 
from the time of diagnosis. Such results could be related to 
the immunomodulatory effect of pregnancy [22]. 
A subsequent meta-analysis that combined the PRIMS 
data with 12 other studies [23] included 1,221 pregnancies. 
A reduction in the mean relapse rate was demonstrated, from 
0.44 in the year before pregnancy to 0.26 during the entire 
pregnancy. The lowest rate (0.18) was observed in the third 
trimester of pregnancy. 
Hughes et al. further confirmed the results obtained by 
the PRIMS study [24]. They found no progression of disa-
bility among women in the analysed period, despite the fact 
that more relapses were observed immediately after delivery. 
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The strongest predictive factor for post-partum MS relapse 
was the relapse rate in the two years preceding pregnancy, 
relapses during pregnancy, a disability score ≥ 2 assessed by 
the Expanded Disability Status Scale (EDSS) at the time of 
conception, and a longer duration of the disease. Other studies 
have also indicated that women with a higher rate of relapses 
before pregnancy have a higher possibility of relapse during 
pregnancy [25–27]. Importantly, Hughes et al. showed that 
administration of DMDs in the two years before pregnancy 
reduced the risk of postpartum MS relapse by 45%, and the 
authors suggested treatment should be continued until pre-
gnancy is confirmed.  
The protective effect on relapses during pregnancy is due to 
immune changes that occur in the female body which protect 
the developing foetus from the maternal immune system. The 
shift from a prevailing Th1 response to Th2-type response, 
with a simultaneous increase in the number of regulatory T 
cells, has been discussed [28]. However, this mechanism is 
probably more complex and also includes changes in cyto-
toxicity of CD56(bright) natural killer cells,  CD4+ T cells 
producing interferon-gamma in the CD4+/CD8+ ratio and 
in the concentration of interleukin 8. 
MS-modifying treatment  
Personalised therapy, which is considered the most 
appropriate approach, is based on selection of the proper drug 
in the right dose for the right patient to obtain the maximum 
effectiveness with the highest standards of safety. Previously, 
the choice of treatment for  patients with MS was relatively 
simple, given that only single drugs were available. To date, 
13 drugs with different mechanisms of action, efficacy and 
safety profile have been registered for MS. Personalisation 
of treatment in the context of family planning remains 
a crucial issue. 
The general principles for selecting the first treatment for 
MS are based on the determination of the benefit/risk profile 
[29–32]. An escalation or an induction approach is chosen de-
pending on the course (classic MS, or rapidly evolving severe, 
RES, respectively). In the former, the therapy is started with the 
first-line DMD (parenteral medications i.e. beta-interferons 
and glatiramer acetate (GA), and oral medicines i.e. dimethyl 
fumarate or teriflunomide) and, if necessary, therapy is esca-
lated when the treatment is not effective. 
Patients with high disease activity may require more 
aggressive immunotherapies from the very beginning, with 
the use of natalizumab, fingolimod, cladribine or ocrelizumab 
(all are second-line drugs in Poland), the last two just recently 
approved for reimbursement in Poland, or alemtuzumab (re-
cently restricted by the European Medicines Agency for use 
in adults with highly active RRMS despite adequate treatment 
with at least one disease-modifying therapy or if the disease 
is worsening rapidly with at least two disabling relapses per 
year and associated MRI activity). 
Pregnancy planning and DMDs in women 
with multiple sclerosis  
Pregnancy planning 
Responsible motherhood requires pregnancy planning in 
MS patients [33–35]. Importantly, hormonal contraceptives 
do not adversely affect the course of the disease, and drugs 
containing high doses of oestrogens may have even beneficial 
anti-inflammatory effects [36, 37]. 
Pregnancy planning should be discussed with patients 
at diagnosis because (as shown by population studies in the 
USA) as many as 50% of pregnancies are unplanned, and the 
highest risk of abnormal foetal development occurs during 
weeks 4–8 of gestation [38]. Patients should be asked about 
whether they wish to have children and about the timing of 
pregnancy. The patient and her partner should have the chance 
to discuss objectively and impartially the issue of parenthood 
and the potential selection of the most appropriate method of 
contraception. The situation should be discussed not only with 
a neurologist but also with the members of the interdiscipli-
nary team that should consist of an obstetrician-gynaecologist 
and a psychologist/psychiatrist. 
From a neurological point of view, disease course and 
activity should be considered when the issue of motherhood 
is discussed. Ideally, there should be a minimum of one year 
between  the time of diagnosis and decision-making about 
a planned pregnancy. This period is necessary to determine the 
course and activity of the disease. Although pregnancy has an 
immunomodulatory effect on MS, studies have shown that it 
should not be recommended in cases of MS with high activity 
and an aggressive course [39, 40]. A good response to DMD 
is defined as no evidence of disease activity (NEDA), both 
clinically and radiologically, for about two years. Obtaining 
such a response is the right moment to decide about becoming 
pregnant [41]. This moment, typically two years following 
the diagnosis, seems the most appropriate at which to risk 
discontinuation of therapy in most patients [42]. Obviously, 
the decision must be made individually by each patient. The 
particular type of DMD should also be considered. 
Comorbidities and the symptoms of MS such as cognitive 
and emotional disorders should also be taken into account 
when the potential risk associated with pregnancy is assessed 
in  patients. 
Table 1 sets out the general criteria for safe pregnancy in 
patients with MS.
When a DMD is selected, attention should be paid to 
disease activity, the potential effect of the drug on pregnancy 
and foetal development, and the risk of relapse when the 
therapy is discontinued. Vitamin D supplementation must 
be considered when pregnancy is planned in MS patients. 
American guidelines recommend a dose of 1,000-2,000 U/
day [43]. Finnish studies showed that a reduced level of 25-hy-
droxyvitamin D [25 (OH) D] (< 12.02 ng/mL) in the mother 
in early pregnancy was associated with a nearly doubled risk 
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Table 1. Criteria for safe pregnancy in multiple sclerosis patients
1. Remission period. 
2. No DMD for a period specific to each drug. 
3. Favourable prognosis of the disease.
4. Intake of folic acid in a prophylactic dose for at least three months 
before a planned pregnancy, and vitamin D supplementation in 
the case of deficiency. 
5. Considering pregnancy during administration of some DMDs in 
individual cases.
DMD — disease-modifying drug
of MS in a child compared to the offspring of women with 
a normal blood level of vitamin D [44]. Patients with MS 
who plan pregnancy should follow the recommendations 
for all future mothers, including smoking cessation, alcohol 
abstinence, termination of stimulant use, following a balan-
ced diet rich in omega-3 polyunsaturated fatty acids, and the 
intake of folic acid.  
DMD in relation to pregnancy and family 
planning 
According to the recommendations of the European Medi-
cines Agency (EMA) related to the impact of medical products 
on reproduction and lactation, a prospective follow-up of at 
least 300, and preferably 1,000, pregnancies is necessary to 
assess the safety of any given product [45]. The use of effec-
tive contraception (also after drug registration) is one of the 
requirements for participation in most clinical trials. During 
therapy, contraception is recommended. Therefore, the data 
on the impact of DMDs (especially newly registered) on foetal 
development are very limited. 
Most DMDs used in the treatment of RRMS are classified 
in the Food and Drug Administration (FDA) pregnancy 
category C, which means that animal reproductive studies 
have shown teratogenic or fatal effects on the foetus. Howe-
ver, there have been no well-controlled studies in women 
or there have been no adequate studies either in animals or 
humans. Classic cytostatic drugs (e.g. mitoxantrone) are in 
FDA pregnancy category D whereas category X was recently 
removed for teriflunomide. Glatiramer acetate (GA) was in 
category B. However, pregnancy has recently been removed 
from the list of contraindications (in the Summary of Product 
Characteristics) for a dose of 20-40 mg of glatiramer acetate, 
but also for interferon beta-1B subcutaneously every other 
day, interferon beta-1A subcutaneously three times a week, 
intramuscular interferon beta-1A every week, and interferon 
beta-1A subcutaneously every two weeks. It must be underli-
ned that the safety data on GA during pregnancy is based on 
observations of the original product. 
It should be noted that pregnancy categories A, B, C, D 
and X, introduced in 1979, have now been replaced with more 
detailed characteristics in the specific sections including e.g. 
pregnancy, delivery and the postpartum period, pregnancy 
registry, breastfeeding, reproductive potential and contra-
ception [46]. 
Previously, all the guidelines recommended discontinu-
ation of treatment before a planned pregnancy, with a ‘wash-
-out’ period of differing durations depending on the drug used. 
Nevertheless, based on real-world data (RWD), experienced
neurologists specialising in MS have continued treatment
with GA, interferon beta (IFN beta) or natalizumab until
confirmation of pregnancy in those patients with a high risk of 
disease reactivation after treatment discontinuation  [47, 48]. 
According to the most recent ECTRIMS/EAN Guidelines 
(2018) [29], patients should be informed that no DMDs sho-
uld be used during pregnancy except for GA or interferons 
beta according to the registration documents. Continuation 
of treatment with GA or IFN beta should be considered 
until confirmation of pregnancy in women with a high risk 
of disease reactivation who plan pregnancy. In exceptional 
(active) cases, continuation of this therapy in pregnancy should 
also be considered. 
Women with persistently high disease activity should be 
recommended to postpone pregnancy. If, however, the patient 
decides to become pregnant, or in an unplanned pregnancy, 
treatment with natalizumab should be considered after a tho-
rough discussion with the patient regarding the potential 
implications.
Cladribine or alemtuzumab (taking into account its recent 
restrictions) could be an alternative option for patients with 
high disease activity who plan pregnancy, provided there is 
a 6-month (or 4-month for alemtuzumab) interval between 
the last dose and the planned conception. 
The guidelines of the American Academy of Neurology 
(AAN 2018) [49] include similar recommendations. In general, 
DMDs should be discontinued before a planned pregnancy 
unless the risk of disease reactivation after discontinuation 
outweighs the risk of their use in pregnancy. It is also recom-
mended to monitor childbearing plans in MS patients and 
pregnancy planning with the use of contraceptives during 
DMD therapy. Pregnancy planning should also apply to 
women whose partners are affected by MS. The AAN guide-
lines indicate the effect of cytostatic drugs on male fertility 
(cyclophosphamide) and the potential teratogenic effect by its 
influence on sperm (teriflunomide) [50]. It is recommended 
to discuss reproductive plans with MS men before the admi-
nistration of these drugs. EAN/ECTRIMS guidelines do not 
provide recommendations for contraception in men treated 
with teriflunomide. According to the Summary of Product 
Characteristics, contraception is not advised for female part-
ners of men who are treated with teriflunomide. Additionally, 
discontinuation of teriflunomide is not recommended for men 
before fatherhood [51].
Discontinuation of treatment that induces chronic 
immunomodulation or immunosuppression often leads 
to disease activation, as in the case of highly active natali-
zumab and fingolimod.  On the other hand, therapies that 
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result in reconstitution of the immune system, which are 
given for a short period of time and lead to long-lasting 
changes in the functioning of the immune system (‘repro-
gramming the immune system’), may lead to long-term 
remission. These include alemtuzumab [52] and cladribine 
[53]. Due to the mechanism of action and dosing, drugs 
that cause reconstitution of the immune system seem to 
be a beneficial alternative to MS patients who plan to have 
children. 
Table 2 sets out a summary of recommendations related 
to disease-modifying treatment in women with MS who plan 
pregnancy. 
Table 3 sets out the characteristics of DMDs in the context 
of pregnancy, based on the current Summaries of Product 
Characteristics and reports from the literature. 
Impact of MS on pregnancy 
Studies have revealed that the percentage of miscarriages 
in MS patients is approximately 20%, similar to the general po-
pulation. The available data confirms that MS does not increase 
the risk of congenital disorders in offspring. The percentage of 
miscarriages remains at a similar level before and after the oc-
currence of the first symptoms of MS, and also among women 
who used DMDs and those who did not use DMDs. Although 
weakness, drowsiness and fatigue typically accompany pregnan-
cy, in MS they may require neurological assessment. 
A higher risk of preterm delivery, inhibited intrauterine 
growth in children, or intrauterine death has not been ob-
served in the course of pregnancy in women with MS [54]. 
Other studies have indicated a  slightly lower mean birth 
weight and a higher occurrence of small-for-gestational-age 
(SGA) births [55]. 
In the case of impaired mobility and paresis of the lower 
limbs, MS patients have an increased risk of thrombosis during 
pregnancy and puerperium. For this reason, compression 
stockings are recommended. Sometimes anticoagulants must 
be administered. 
Single reports have indicated a higher incidence of UTIs 
during pregnancy in women with MS. Patients with fun-
ctional disorders of the lower urinary tract secondary to MS 
must be aware of the exacerbation of these symptoms during 
pregnancy.  
Treatment of relapses in multiple sclerosis 
during pregnancy 
If an acute severe MS relapse occurs during pregnancy, tre-
atment aimed at improving the general condition, accelerating 
recovery and creating the conditions for better development of 
pregnancy should be considered. The primary treatment of re-
lapse is intravenous methylprednisolone 1 g daily for 3–5 days. 
Non-fluorinated glucocorticosteroids (prednisone and 
methylprednisolone) poorly cross the placenta (≤ 10%). They 
are mostly metabolised by placental 11-beta-hydroxysteroid 
dehydrogenase, which results in low concentrations in foetal 
blood and their use in the second and third trimesters is 
considered safe [56]. There are reports of possible lower 
birth weight and a slightly higher risk of preterm delivery. 
Methylprednisolone (iv) is in pregnancy category C. However, 
the risk of cleft lip and low birth weight is increased when it 
is used in the first trimester.  
Fluorinated glucocorticoids (betamethasone, dexametha-
sone) are not recommended as they cross the placenta and are 
detected in the foetal blood at relatively high concentrations. 
These drugs may be used in short-term treatment in cases 
Table 2. Summary of recommendations related to disease-modifying treatment in women with MS who plan pregnancy
1.  In women with active disease, decision to start treatment with DMD should not be delayed, as long as patient is not pregnant yet. Effective contra-
ception must be planned. 
2.  According to current ECTRIMS/EAN guidelines (2018), when a patient with MS plans pregnancy, patient’s clinical condition must be established first 
(i.e. no disease activity for at least 1-2 years) and then attempts at pregnancy should be made. 
3.  Risk of relapse associated with drug withdrawal should be considered when deciding on DMD therapy (especially in the case of natalizumab and 
fingolimod). Possibility of effective elimination of the drug from serum (teriflunomide) should also be taken into consideration. 
4.  In the event of high risk of disease reactivation during pregnancy, continuation of treatment with IFN beta or GA may be considered until confirmation 
of pregnancy. 
5.  DMD therapy is not recommended during pregnancy. Continuation of therapy with GA (possible in Poland according to the Summary of Product Cha-
racteristics) or with interferons beta (possible according to the Summary of Product Characteristics for interferon beta 1-B subcutaneously every other 
day, interferon beta-1A subcutaneously three times weekly, intramuscular interferon beta-1A every week, interferon beta-1A subcutaneously every 
two weeks) may be considered in selected cases (in active disease) if the potential benefit outweighs risk associated with therapy.
6.  Continuation of treatment with natalizumab during pregnancy should be considered (not possible under the Polish NHF drug programme due to no 
indications in Summary of Product Characteristics) after thorough discussion with patients on potential implications (e.g. haematological disorders of 
newborn) in the case of patients with high disease activity who are treated with natalizumab and intend to be pregnant when disease stabilisation is 
not achieved.
7.  During an aggressive course of the disease, it is necessary to consider such therapy, the discontinuation of which will not be related to risk of reacti-
vation (cladribine or alemtuzumab). During such treatment, patients can plan pregnancy four months after last dose of alemtuzumab and six months 
after last dose of cladribine.
DMD — disease-modifying drug; MS — multiple sclerosis; IFN — interferon; GA —glatiramer acetate; NHF — Polish National Health Fund
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Table 3. Characteristics of disease-modifying therapies in MS in the context of pregnancy based on the current summaries of the product characteristics and 
literature reports
Glatiramer acetate (GA)
•	 molecular weight of 5-9 kDa
•	 no excretion into breast milk or via the placenta, allowed during breastfeeding
•	 t½ of about 20 hours
•	 no relationship between GA and the unfavorable course of pregnancy: GA is safe in early pregnancy and treatment can be continued until pre-
gnancy is confirmed and also during pregnancy in cases of high disease activity
•	 GA can be used during pregnancy according to the Polish National Health Fund program B.29
Beta-interferons (IFNs-beta)
•	 molecular weight of IFN beta-1b is 18.5 kDa and IFN beta-1a 22.5 kDa
•	 low risk of excretion into breast milk or via the placenta, interferons beta-1A and beta-1B are allowed during breastfeeding
•	 t½ of 5 hours (IFN beta-1b), 10 hours (IFN beta-1a intramuscular), 50 hours (IFN beta-1a subcutaneously) and 78 hours (PEGylated IFN beta-1a)
•	 IFN beta seems to be safe until pregnancy is confirmed
•	 the use of IFN beta-1A and beta-1B preparations can also be considered during pregnancy in the case of high disease activity
Dimethyl fumarate
•	 molecular weight of the active metabolite is 125 Da
•	 no data on excretion into breast milk
•	 t½ of about 1 hour, the drug is poorly bound to plasma proteins and is poorly accumulated in the tissues
•	 it is recommended to discontinue the drug before the planned conception; however, it should be noted that due to the very short t½ (about 1 
hour) and minimal accumulation of the drug in the tissues, it is rapidly eliminated from the body
•	 in the case of unplanned pregnancy, dimethyl fumarate should be discontinued and ultrasound screening for possible fetal defects should be considered
•	 patients treated with dimethyl fumarate must use contraception (also according to the Polish National Health Fund program B.29)
Teriflunomide
•	 molecular weight of about 270 Da
•	 excretion into breast milk in animal studies
•	 t½ of 15-18 days; however, clinically insignificant plasma concentration <0.02 mcg/ml after discontinuation of the treatment is reached after 8 months, 
and sometimes as late as after 2 years
•	 highly bound to plasma proteins (99%)
•	 effective contraception during the treatment must be used
•	 if pregnancy is planned, treatment must be discontinued and the accelerated drug elimination procedure must be implemented, typically with cho-
lestyramine (8 g, 3 times/day for 11 days); drug concentration must be assessed in the blood using two determinations at an interval of at least 14 days; 
prior to the planned fertilization, patients have to wait for 1.5 months after the first confirmation of teriflunomide concentration < 0.02 mcg/ml
•	 in the case of unintended pregnancy, the procedure of the accelerated elimination of the drug must be implemented immediately and ultrasound 
screening for fetal congenital defects must be performed;
•	 teriflunomide concentration in the semen of male patients is very low (100 times lower than blood concentration, after a dose of teriflunomide 14 mg 
p.o.); low risk of transmission of teriflunomide by the male reproductive system, which could have a detrimental effect on the embryo or fetus
•	 patients treated with teriflunomide must use contraception (also according to the Polish National Health Fund program B.29)
Natalizumab
•	 molecular weight of 149 kDa
•	 t½ of 11 ± 4 days
•	 excreted into breast milk
•	 actively transported through the placental barrier (starting from the second trimester)
•	 currently, a slightly increased risk of miscarriage and fetal congenital defects cannot be ruled out — further follow-up is warranted
•	 there is a risk of hematological disorders in children of patients with high disease activity treated with natalizumab throughout the entire pregnancy
•	 there is a risk of disease activation, even with the rebound effect, after discontinuation of natalizumab and also during pregnancy in individual cases
•	 the conservative approach requires discontinuation of natalizumab 3 months before the planned pregnancy, which seems rather risky in view of 
disease activation
•	 a less conservative approach recommends discontinuation of natalizumab when attempting conception;
•	 the least conservative approach recommends discontinuation of the drug only when pregnancy is confirmed; when the disease becomes active during 
pregnancy, re-initiation of treatment with natalizumab is recommended at a dose of 300 mg every 6 weeks and discontinuation of therapy before 
week 30 of pregnancy (in such cases, the newborn should be examined for hematological disorders)
•	 patients treated with natalizumab must use contraception (according to the Polish National Health Fund program B.46)
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Table 3. cont. Characteristics of disease-modifying therapies in MS in the context of pregnancy based on the current summaries of the product characteri-
stics and literature reports
Fingolimod
•	 molecular weight of 344 kDa
•	 t½ of 6-9 days; very high bioavailability (95%) after oral administration
•	 excretion into breast milk of animals during lactation
•	 teratogenic effect in animal studies; the drug crosses the placental barrier and affects angiogenesis, cardiogenesis and neurogenesis by modulating 
S1P receptors found in many tissues
•	 currently, the teratogenic effect of fingolimod is not ruled out in humans; women treated with fingolimod should use effective contraception and 
should not plan pregnancy until 2 months after discontinuation of the therapy
•	 in the case of unplanned pregnancy, the treatment with fingolimod must be discontinued and ultrasound screening for fetal congenital defects should 
be performed
•	 patients treated with fingolimod must use contraception (also according to the Polish National Health Fund program B.46)
Alemtuzumab
•	 molecular weight of 150 kDa
•	 t½ of 4-5 days
•	 crosses the placenta, no data on excretion into breast milk
•	 an increased risk of miscarriage and lymphopenia as a result of treatment (animal studies); quite a high percentage of spontaneous abortions in hu-
mans
•	 pregnancy must be excluded before each treatment cycle of alemtuzumab (negative pregnancy test)
•	 contraception is recommended for 4 months following the last dose of alemtuzumab (the drug is completely eliminated from the body within 30 
days after administration)
•	 patients	must	 be	monitored	 for	 secondary	 autoimmune	 complications	 and	 their	 potential	impact	on	pregnancy	in	patients	who	become	pregnant
after the post-therapy contraception period
•	 patients	 treated	 with	 alemtuzumab	 must	 use	 contraception	 (also	 according	 to	 the	 Polish	National	Health	Fund	program	B.29)
Cladribine
•	 molecular	weight	of	285.687	kDa
•	 no	data	on	excretion	into	breast	milk
•	 t½ of about 1 day; 20% bound to plasma proteins
•	 teratogenic	effect	in	mice	and	rabbits;	an	adverse	effect	on	gamete	formation	can	be	expected	in	humans
•	 pregnancy	must	be	ruled	out	before	drug	administration
•	 cladribine-treated	patients	must use effective contraception during treatment and 6 months following the last administration of cladribine; me-
chanical contraception must be additionally used in patients who use systemic contraceptives during the treatment with cladribine and for 4 weeks 
immediately after the last dose of the drug
•	 women	 who	become	 pregnant	 during	 treatment	 with	cladribine	 should	 discontinue	 the	treatment	immediately	and	ultrasound	screening	for	fetal
congenital defects should be performed
• men	treated	with	cladribine	should	use	contraception	during	the	treatment	and	for	6	months	following	the	last	dose	to	prevent	pregnancy	in	their	partners
Ocrelizumab
•	 molecular	weight	of	145	kDa
•	 no	data	on	excretion	into	breast	milk,	the	drug	crosses	the	placental	barrier
•	 t½ of 28 days (on average)
•	 no	data	on	safety	in	pregnancy	(FDA)
•	 decreased	B-cells	and	transient	lymphopenia	in	children	of	mothers	treated	with	anti-CD20	antibodies	during	pregnancy
•	 women	treated	with	ocrelizumab	should	use effective contraception during treatment and 12 months after the last dose
•	 the	pregnancy	registry	is	planned	in	patients	treated	with	ocrelizumab
Mitoxantrone
•	 molecular	weight	of	517	kDa
•	 t½ of 23-215 hours; slowly eliminated from the body – it is detectable in tissues after 9 months following the last administration; 78% bound to plasma proteins
•	 excretion	into	breast	milk
•	 teratogenic	effect	in	animals	and	humans
•	 women	treated	with	mitoxantrone	must	use	effective	contraception;	both men and women should not plan pregnancy within 6 months following 
the last administration
•	 the	treatment	with	mitoxantrone	can	cause	menstrual	disorders,	including	permanent	amenorrhea,	particularly	in	women	over	35	years	of	age	(42%	of	
cases); transient azoospermia (3-4 months) has been reported in men treated with mitoxantrone due to Hodgkin’s lymphoma.
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of the onset of preterm delivery in order to accelerate foetal 
lung maturation. 
If no improvement is observed after the first course of 
steroid therapy, another administration of methylprednisolone 
or intravenous immunoglobulins can be administered (cate-
gory C; FDA). There is no established regimen for the use of 
immunoglobulins (IgGs). Typically, they are given in a dose of 
0.2-0.4 g/kg body weight for five consecutive days. The use of 
IgGs in women with active disease during pregnancy to reduce 
the risk of relapse after delivery is currently not recommended. 
Such management, based on previous open studies which 
postulated a reduction in the increased number of relapses 
in the postpartum period by intravenous administration of 
IgG [57, 58], was not confirmed in randomised studies [59, 
60]. A prompt return to immunomodulatory treatment is 
recommended [61–63]. 
Additional management in pregnancy  
Treatment of infections 
Bladder dysfunction in women with MS may lead to 
a higher susceptibility to UTIs, which may result in exacerbation 
of the underlying disease. For this reason, in addition to routine 
urine tests, a urine culture should be performed in these patients 
at least once a month to detect asymptomatic UTIs. In both 
symptomatic and asymptomatic UTIs, the standard pharma-
cological treatment is recommended for 7–10 days, preferably 
according to the antibiogram. One week after the end of therapy, 
a follow-up urine culture should be performed. In the case of 
recurrent UTIs, pharmacological treatment should last for 
14 days with subsequent prophylaxis of infections until the end 
of pregnancy by using one dose of an antibiotic or antimicrobial 
agent at night. Ultrasound investigation of the urinary tract 
is also recommended to detect other potential abnormalities. 
Maintenance of physical activity 
Physical activity and a balanced diet are the two most impor-
tant factors improving the well-being and increasing the physical 
ability of MS patients. During pregnancy, physical activity is of 
importance not only to the well-being of pregnant women, but 
also since it allows reducing the risk of venous thromboembolic 
disease. Even though one of the predominant symptoms is incre-
ased fatigue, patients should not abandon active participation in 
everyday life. Most importantly, physical activity should be adap-
ted to the stage of the disease and the overall physical capacity of 
the woman. Physical exercises must be safe and should improve 
their well-being. General physical activity and water exercises 
are recommended. In cases of reduced mobility, a prophylactic 
dose of low molecular weight heparin should be considered. 
Delivery, feeding and puerperium 
Multiple sclerosis is not a contraindication to natural 
delivery. However, impairment of physical fitness can make 
pushing more difficult. For this reason, surgical delivery is 
more prevalent in this group of women. Elective Caesarean 
section is performed in patients with severe motor disability. 
Epidural anaesthesia during delivery is not contraindicated 
for patients with MS. 
It does not affect the subsequent risk of relapse or progres-
sion of disability. It should be borne in mind that women with 
MS have a higher risk of perinatal depression [64]. 
Women with MS can breastfeed unless they are on a DMD. 
An influence of lactation on the relapse rate has not been 
observed [65, 66]. In accordance with the current Summary 
of Product Characteristics, drug-related risk should always be 
considered when the therapy is continued during breastfee-
ding. Within four weeks after delivery, neurological assessment 
and optional magnetic resonance imaging are indicated to 
determine when DMD treatment is continued. 
Contraception in MS patients 
There is no doubt that highly effective contraception 
should be used during DMD treatment that is potentially 
teratogenic. 
According to the guidelines of the World Health Orga-
nisation (WHO) [67, 68] and the recommendations of the 
American Centers for Disease Control and Prevention (CDC) 
[69], MS patients without immobilisation are included in 
Category 1 (no restriction for the use of the contraceptive 
method). Therefore, there are no contraindications for the use 
of intrauterine devices, levonorgestrel-releasing intrauterine 
systems, progestogen-only pills, agents containing oestrogens 
and progestogens such as contraceptive vaginal rings con-
taining hormones, oral contraceptive pills, and transdermal 
contraceptive patches. 
In this group of patients, only intramuscular administra-
tion of sustained-release medroxyprogesterone acetate (depot 
medroxyprogesterone acetate; DMPA) was included in Catego-
ry 2, which means that the benefits of the method outweigh the 
potential risk. In the case of chronically immobilised patients, 
contraceptives containing silver, copper or levonorgestrel, 
progestogen-only pills and implants are included in Catego-
ry 1. The use of  intramuscular sustained-release DMPA is 
classified in Category 2, and the combined contraceptive pill, 
contraceptive vaginal rings and patches in Category 3, which 
means that their use is associated with a risk of complications. 
However, they are not absolutely contraindicated [70, 71]. 
It is known that the use of some contraceptive methods is 
associated with a risk of complications. The most common of 
these related to the combined contraceptive pill include venous 
thromboembolic disease, vascular diseases, deterioration in 
hypertension control, decreased libido, and decreased mood 
[67-69]. Long-term intramuscular injections of DMPA may 
result in decreased bone mass and the occurrence of abnor-
mal genital bleeding. These adverse effects mostly disappear 
soon after drug discontinuation. However, subcutaneous 
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etonogestrel implants may be safer in such situations as they 
do not cause bone loss. 
Urinary incontinence and urinary 
complaints in MS patients during pregnancy 
and after delivery  
Detrusor overactivity is the most common form of voi-
ding disorder. It is usually associated with detrusor sphincter 
dyssynergia (functional obstruction). Underactivity or no 
contractile function of the detrusor is rare in the early form 
of the disease, whereas in advanced forms it is the most com-
mon cause of urinary retention and cessation. In a significant 
proportion of patients with MS, impaired lower urinary tract 
function changes with disease course. The intensity of the 
lower urinary tract dysfunction generally correlates with the 
level of disability. 
Pregnancy and delivery increase lower urinary tract dys-
function, especially overactivity and impaired coordination 
between detrusor and sphincter. For this reason, increased 
urinary retention after voiding and the development of secon-
dary UTIs are much more prevalent during pregnancy. The 
treatment of voiding disorders in MS patients depends on the 
type of voiding disorder and the degree of disability [72–74]. 
In addition, recurrent UTIs and the risk of renal failure should 
also be considered.
Lifestyle modifications (urinating by the clock, reaso-
nable fluid intake, caffeine restriction) and bladder training 
(extending the time between voiding by 30 minutes at weekly 
intervals) are useful in the case of polyuria and urinary urgen-
cy in the initial stage of the disease. The treatment includes 
antimuscarinics (tolterodine, solifenacin, oxybutynin) and 
beta-adrenergic agonists. However, in MS patients oxybutynin 
is not recommended as they are at risk of urinary retention. 
Mirabegron is the only representative of beta-adrenomimetics 
that does not significantly increase urinary retention due to 
the bladder-relaxant effect only in the filling phase. Botulinum 
toxin can also be used in the overactive bladder (100–300 units 
of onabotulinum toxin), with over 80% effectiveness. It can 
be obtained provided that patients can perform self-cathete-
risation after its use. A single administration of the toxin is 
usually sufficient for 6-9 months.
Functional bladder obstruction in MS patients results in 
increased urinary retention after voiding, weakened urinary 
stream and, consequently, detrusor muscle failure. Pharmaco-
logical treatment of functional bladder obstruction is poorly 
effective. Alpha-adrenolytic drugs (doxazosin, tamsulosin, si-
lodosin, alfuzosin) are used to relax the bladder neck, whereas 
muscle relaxants (e.g. baclofen) are used to relax the external 
urethral sphincter. Pharmacological treatment of functional 
bladder obstruction is effective only in the initial period. Bo-
tulinum toxin administered to the external urethral sphincter 
is used in the treatment of functional obstruction (≤ 100 U of 
onabotulinum toxin, soft label use). 
Self-catheterisation is the management of choice in the 
case of severe bladder obstruction with significant retention. 
The volume of residual urine which is associated with a higher 
prevalence of UTIs is above 150 ml. Volumes > 25% of the fun-
ctional bladder capacity are considered clinically significant. 
Intermittent self-catheterisation is contraindicated when urinary 
retention volume is < 100 ml. The frequency of intermittent 
self-catheterisation is determined by diurnal diuresis, the fun-
ctional bladder capacity, and residual urine after voiding. It is 
assumed that the volume of urine in the bladder should not 
exceed 400–500 ml. No-touch intermittent catheterisation is 
a recommended technique which involves single-use hydrophilic 
catheters. Small diameter catheters (10–12 Fr) of different lengths 
for women, men and children should be used. Catheters for 
women are shorter and more rigid than catheters for men [75]. 
Stress urinary incontinence associated with insufficient 
strength of the pelvic floor muscles is common in women 
with MS. It is the mechanical weakening of the suspensory 
apparatus of the urethra rather than damage to the inner-
vation. The usual treatment of stress urinary incontinence 
is surgery and suburethral tape implantation. However, in 
patients with MS, complications should be expected in the 
form of increased overactivity, decreased bladder contracti-
lity, and urinary retention after voiding. Therefore, from the 
urological perspective, pregnancy in patients with MS should 
be carefully planned, preferably after intensive remission-
-targeted treatment [76].
Conclusions and recommendations 
1.  Pregnancy in MS patients should be planned, which requires 
interdisciplinary co-operation with a neurologist, a gyna-
ecologist and sometimes also a psychologist.
2.  Counselling for young women with MS is necessary with
regards to effective methods of contraception. These are
selected individually for the patient (oral, implant, or in-
trauterine contraceptive device).
3.  No DMD is 100% safe during pregnancy. According to
the Summary of the Product Characteristics, glatiramer
acetate at a dose of 20 mg subcutaneously every day or
40 mg subcutaneously three times a week, interferon beta-
-1B subcutaneously every other day, interferon beta-1A
subcutaneously three times a week, intramuscular interferon 
beta-1A every week, and interferon beta-1A subcutaneo-
usly every two weeks, are the only drugs that can be used
during pregnancy (after considering the potential benefits
and risks). The safety guidelines on GA during pregnancy
are based on observations of the original GA.
4.  In women with childbearing potential, it is necessary:
I. to determine the form of MS and to choose the treat-
ment method accordingly and in line with the current
guidelines.
II. to determine decisions related to pregnancy planning
when:
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a)  the patient wishes to become pregnant; pregnancy 
is recommended after the follow-up of disease acti-
vity and response to treatment for about two years 
after treatment onset. The drug elimination period 
must be considered when planning a pregnancy.
In the case of high disease activity, neurological
stabilisation should be achieved before planning
pregnancy. Treatment that will not result in an
increased risk of disease activation when therapy is 
discontinued should be considered (e.g. cladribine 
or alemtuzumab);
b)  the patient does not want to become pregnant within 
the next two years or already has offspring, and uses
effective contraception. In such cases, the reproducti-
ve age does not have to influence the choice of DMD; 
c) the patient does not want to become pregnant within
the next two years or already has offspring; neither
does the patient comply with contraception guideli-
nes. In such cases, the preferred therapy is GA or beta 
interferons.
5. Discontinuation of treatment in relation to a planned
pregnancy is associated with a risk of increased disease
activity, which is particularly related to patients treated
with natalizumab and fingolimod.
6. Gynaecologists should be informed about possible adverse 
effects of DMD therapy by the attending neurologist.
7. In the second and third trimesters of pregnancy, relapses
should be treated with nonfluorinated steroids (prednisone 
and methylprednisolone) in standard doses (0.5-1.0 g/day 
of methylprednisolone iv for 3–5 days). In the first trime-
ster, administration of steroids is associated with a risk of 
foetal defects and low birth weight. In such cases, intrave-
nous human IgGs may be considered in a standard dose of 
0.4 g/kg body weight for five consecutive days.
8. Patients with MS have a higher risk of perinatal depression.
Both the gynaecologist and the patient/family must be in-
formed about the risk of depression and suicidal thoughts. 
9. Within four weeks after delivery, a neurological assessment 
is indicated with magnetic resonance imaging (if needed) 
to determine when DMD treatment is re-administered.
A rapid return to DMD treatment is recommended after
pregnancy.
10.  Pregnancy planning should also be related to women
whose partner has been diagnosed with MS.
11.  It is recommended to discuss reproductive plans with men 
diagnosed with MS before the inclusion of DMD treat-
ment, and to consider sperm banking before treatment.
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